A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study

References

• Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676–681. doi:10.1053/j.seminoncol.2016.11.004.
   PubMed Web of Science ®Google Scholar
• Chang-Chan DYL, Ríos-Tamayo R, Rodríguez Barranco M, et al. Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study. Clin Transl Oncol. 2021;23(7):1429–1439. doi:10.1007/s12094-020-02541-1.
   PubMed Web of Science ®Google Scholar
• Laubach JP, Mitsiades CS, Mahindra A, et al. Novel therapies in the treatment of multiple myeloma. J Natl Compr Cancer Netw. 2009;7(9):947–960. doi:10.6004/jnccn.2009.0062.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol. 2013;40(5):634–651. doi:10.1053/j.seminoncol.2013.07.007.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728–734. doi:10.1200/JCO.2017.76.5032.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017;7(4):e554. doi:10.1038/bcj.2017.31.
   PubMedGoogle Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133–2142. doi:10.1056/NEJMoa070596.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123–2132. doi:10.1056/NEJMoa070594.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Orlowski RZ, Facon T, et al. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015;100(1):100–106. doi:10.3324/haematol.2014.112037.
   PubMed Web of Science ®Google Scholar
• Kouroukis TC, Baldassarre FG, Haynes AE, et al. Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol. 2014;21(4):e573–e603. doi:10.3747/co.21.1798.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2014;372(2):142–152. doi:10.1056/NEJMoa1411321.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38. doi:10.1016/S1470-2045(15)00464-7.
   PubMed Web of Science ®Google Scholar
• Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–1066. doi:10.1016/S1470-2045(13)70380-2.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–157. doi:10.1038/leu.2011.196.
   PubMed Web of Science ®Google Scholar
• Weinhold N, Ashby C, Rasche L, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128(13):1735–1744. doi:10.1182/blood-2016-06-723007.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067–1076. doi:10.1182/blood-2012-01-405985.
   PubMed Web of Science ®Google Scholar
• Cuesta-Mateos C, Alcaraz-Serna A, Somovilla-Crespo B, et al. Monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets. Front Immunol. 2018;8:1936. doi:10.3389/fimmu.2017.01936.
   PubMed Web of Science ®Google Scholar
• Sanchez L, Wang Y, Siegel DS, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(1):51. doi:10.1186/s13045-016-0283-0.
   PubMed Web of Science ®Google Scholar
• Xia C, Ribeiro M, Scott S, et al. Daratumumab: monoclonal antibody therapy to treat multiple myeloma. Drugs Today. 2016;52(10):551–560. doi:10.1358/2016.52.10.2543308.
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38 + immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394. doi:10.1182/blood-2015-12-687749.
   PubMed Web of Science ®Google Scholar
• Adams HC, Stevenaert F, Krejcik J, et al. High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytom A. 2018;95(3):279–289. doi:10.1002/cyto.a.23693.
   PubMedGoogle Scholar
• EMA. Summary of product characteristics. DARZALEX 20 ng/mL. 2012. Available from: https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf.
   Google Scholar
• Janssen [Data on File]. Number of patients treated with DARZALEX worldwide as of June 30th, 2022. RF-228132.
   Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331. doi:10.1056/NEJMoa1607751.
   PubMed Web of Science ®Google Scholar
• Spencer A, Lentzsch S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103(12):2079–2087. doi:10.3324/haematol.2018.194118.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103(12):2088–2096. doi:10.3324/haematol.2018.194282.
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Usmani SZ, San-Miguel J, et al. Four-year follow-up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in relapsed or refractory multiple myeloma (RRMM). Blood. 2019;134(Supplement_1):1866. doi:10.1182/blood-2019-123483.
   Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766. doi:10.1056/NEJMoa1606038.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Sonneveld P, Hungria V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20(8):509–518. doi:10.1016/j.clml.2019.09.623.
   PubMed Web of Science ®Google Scholar
• Weisel KC, Sonneveld P, Mateos M-V, et al. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients (pts) with multiple myeloma (MM): four-year update of castor. Blood. 2019;134(Supplement_1):3192. doi:10.1182/blood-2019-123527.
   Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. P05: Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with previously treated multiple myeloma: overall survival results from the phase 3 POLLUX trial. HemaSphere. 2022;6:13. doi:10.1097/01.HS9.0000829592.26407.09.
   Google Scholar
• Sonneveld P, Chanan-Khan A, Weisel K, et al. P04: Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone alone in patients with previously treated multiple myeloma: overall survival results from the phase 3 CASTOR trial. HemaSphere. 2022;6:12. doi:10.1097/01.HS9.0000829588.31575.a9.
   Google Scholar
• Davies F, Rifkin R, Costello C, et al. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann Hematol. 2021;100(9):2325–2337. doi:10.1007/s00277-021-04534-8.
   PubMed Web of Science ®Google Scholar
• Duarte PJ, Schutz NP, Ochoa P, et al. Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma múltiple. Expert Rev Hematol. 2021;14(3):315–322. doi:10.1080/17474086.2021.1886073.
   PubMed Web of Science ®Google Scholar
• Harvanová Ľ, Štulajterová V, Guman T, et al. Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia. Neoplasma. 2021;68(3):626–630. doi:10.4149/neo_2021_201113N1223.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Staderini M, Pilerci S, et al. Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience. Leuk Lymphoma. 2020;61(13):3255–3258. doi:10.1080/10428194.2020.1802452.
   PubMed Web of Science ®Google Scholar
• McMillan A, Basu S, Karunanithi K, et al. Daratumumab, bortezomib and dexamethasone (DVd) at first relapse for patients with relapsed/ refractory multiple myeloma (RRMM): a UK myeloma research alliance (UK-MRA) real-world multicentre analysis. Blood. 2021;138(Supplement 1):4120. doi:10.1182/blood-2021-147043.
   Google Scholar
• Lovas S, Varga G, Farkas P, et al. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients. Int J Hematol. 2019;110(5):559–565. doi:10.1007/s12185-019-02715-w.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869. doi:10.1200/JCO.2015.61.2267.
   PubMed Web of Science ®Google Scholar
• MedDRA. Medical dictionary for regulatory activities (MedDRA). Available from: https://www.meddra.org/.
   Google Scholar
• CTEP. Common terminology criteria for adverse events (CTCAE) v6.0. 2012. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60.
   Google Scholar
• Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34(7):1875–1884. doi:10.1038/s41375-020-0711-6.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23(11):2147–2152. doi:10.1038/leu.2009.147.
   PubMed Web of Science ®Google Scholar
• Lahuerta J-J, Paiva B, Vidriales M-B, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017;35(25):2900–2910. doi:10.1200/JCO.2016.69.2517.
   PubMed Web of Science ®Google Scholar
• SEHH. Guía de mieloma múltiple grupo Español de mieloma. 2021. Available from: https://www.sehh.es/publicaciones/guias-recomendaciones/123889-guias-recomendaciones-2020-2019.
   Google Scholar
• Cedena M, Puig N, Paiva B, et al. Enfermedad mínima residual en la práctica clínica de pacientes con mieloma múltiple, C0-013. LXI Congreso nacional de la sociedad Española de hematología y hemoterapia Valencia, España, 24-26 de Octubre, 2019. Hematologíca. 2019;104(S3):1–470.
   PubMedGoogle Scholar
• Janssen [Data on File]. Cavex program Spain_ Affidavit. as of June 30th, 2022. RF-234641.
   Google Scholar
• Palumbo A, Rajkumar SV, San Miguel JF, et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587–600. doi:10.1200/JCO.2013.48.7934.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396–406. doi:10.3324/haematol.2015.129189.
   PubMed Web of Science ®Google Scholar
• Delforge M, Vekemans M-C, Anguille S, et al. Real-world outcomes for standard-of-care treatments in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):4075. doi:10.1182/blood-2021-146250.
   Google Scholar
• Katodritou E, Vadikolia C, Lalagianni C, et al. “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Ann Hematol. 2013;93(1):129–139. doi:10.1007/s00277-013-1841-y.
   PubMed Web of Science ®Google Scholar
• Rocchi S, Tacchetti P, Pantani L, et al. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Hematol Oncol. 2021;39(1):41–50. doi:10.1002/hon.2820.
   PubMed Web of Science ®Google Scholar
• EFPIA. EFPIA patients W.A.I.T. indicator 2020 survey. 2021. Available from: https://www.efpia.eu/media/602652/efpia-patient-wait-indicator-final-250521.pdf.
   Google Scholar
• Rodríguez-Lescure A, de la Peña FA, Aranda E, et al. Study of the Spanish society of medical oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain. Clin Transl Oncol. 2020;22(12):2253–2263. doi:10.1007/s12094-020-02366-y.
   PubMed Web of Science ®Google Scholar